Page last updated: 2024-09-05

atropine and olanzapine

atropine has been researched along with olanzapine in 12 studies

Compound Research Comparison

Studies
(atropine)
Trials
(atropine)
Recent Studies (post-2010)
(atropine)
Studies
(olanzapine)
Trials
(olanzapine)
Recent Studies (post-2010) (olanzapine)
26,7111,2591,6976,3391,3402,383

Protein Interaction Comparison

ProteinTaxonomyatropine (IC50)olanzapine (IC50)
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)0.097
Muscarinic acetylcholine receptor M4Homo sapiens (human)0.155
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)0.047
Muscarinic acetylcholine receptor M5Homo sapiens (human)0.04
Alpha-2A adrenergic receptorHomo sapiens (human)0.541
Polyunsaturated fatty acid lipoxygenase ALOX15Oryctolagus cuniculus (rabbit)2.768
D(2) dopamine receptorHomo sapiens (human)0.118
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)0.047
Alpha-2B adrenergic receptorHomo sapiens (human)0.421
Alpha-2C adrenergic receptorHomo sapiens (human)0.531
Muscarinic acetylcholine receptor M3Homo sapiens (human)0.392
D(1A) dopamine receptorHomo sapiens (human)0.072
D(4) dopamine receptorHomo sapiens (human)0.173
Alpha-1D adrenergic receptorHomo sapiens (human)0.092
5-hydroxytryptamine receptor 2AHomo sapiens (human)0.038
5-hydroxytryptamine receptor 2CHomo sapiens (human)0.021
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)0.047
Sodium-dependent serotonin transporterHomo sapiens (human)1.033
Histamine H1 receptorHomo sapiens (human)0.013
D(3) dopamine receptorHomo sapiens (human)0.078
5-hydroxytryptamine receptor 2BHomo sapiens (human)0.057
5-hydroxytryptamine receptor 6Homo sapiens (human)0.013
D(2) dopamine receptorRattus norvegicus (Norway rat)0.158
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)0.2028

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (41.67)29.6817
2010's7 (58.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Topliss, JG; Yoshida, F1
Ahman, M; Holmén, AG; Wan, H1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Bellman, K; Knegtel, RM; Settimo, L1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Brar, JS; Chengappa, KN; Kirshner, MA; Levine, J; Parepally, H; Pollock, BG; Zoretich, RA1
Joosen, MJ; Jousma, E; Kuijpers, WC; Lucassen, PJ; Smit, AB; van den Boom, TM; van Helden, HP1
Bourguignon, JJ; Carnicella, S; Mongeot, A; Oberling, P1
Andrade, C; Bambole, V; Bang, A; Shah, N; Sonavane, S1

Reviews

1 review(s) available for atropine and olanzapine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

1 trial(s) available for atropine and olanzapine

ArticleYear
Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine.
    Journal of clinical psychopharmacology, 2000, Volume: 20, Issue:3

    Topics: Adult; Antipsychotic Agents; Atropine; Autonomic Nervous System Diseases; Benzodiazepines; Cholinergic Antagonists; Clozapine; Female; Humans; Male; Muscarinic Antagonists; Olanzapine; Pirenzepine; Psychiatric Status Rating Scales; Psychotic Disorders; Radioligand Assay; Receptors, Muscarinic

2000

Other Studies

10 other study(ies) available for atropine and olanzapine

ArticleYear
QSAR model for drug human oral bioavailability.
    Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13

    Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship

2000
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
    Journal of medicinal chemistry, 2009, Mar-26, Volume: 52, Issue:6

    Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry

2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
    Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3

    Topics:

2008
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
    Pharmaceutical research, 2014, Volume: 31, Issue:4

    Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation

2014
Long-term cognitive deficits accompanied by reduced neurogenesis after soman poisoning.
    Neurotoxicology, 2009, Volume: 30, Issue:1

    Topics: Acetylcholine; Acetylcholinesterase; Animals; Atropine; Benzodiazepines; Cholinesterase Reactivators; Corpus Striatum; Doublecortin Protein; Hippocampus; Male; Maze Learning; Neurogenesis; Olanzapine; Oximes; Pyridinium Compounds; Rats; Rats, Sprague-Dawley; Seizures; Soman

2009
Prefrontal cortex and reversion of atropine-induced disruption of the degraded contingency effect by antipsychotic agents and N-desmethylclozapine in rats.
    The international journal of neuropsychopharmacology, 2010, Volume: 13, Issue:1

    Topics: Animals; Antipsychotic Agents; Atropine; Benzodiazepines; Clozapine; Conditioning, Classical; Drug Interactions; Haloperidol; Male; Muscarinic Antagonists; Olanzapine; Prefrontal Cortex; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley

2010
Continuation of ECT after recovery from transient, ECT-induced, postictal cortical blindness.
    The journal of ECT, 2012, Volume: 28, Issue:1

    Topics: Adolescent; Anti-Dyskinesia Agents; Antipsychotic Agents; Atropine; Benzodiazepines; Blindness, Cortical; Electroconvulsive Therapy; Female; Glycopyrrolate; Haloperidol; Humans; Muscarinic Antagonists; Olanzapine; Panic; Schizophrenia, Paranoid; Treatment Outcome; Trihexyphenidyl

2012